GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (STU:5HU) » Definitions » Beta

Hemogenyx Pharmaceuticals (STU:5HU) Beta : 0.37 (As of May. 21, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Hemogenyx Pharmaceuticals Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-21), Hemogenyx Pharmaceuticals's Beta is 0.37.


Hemogenyx Pharmaceuticals Beta Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals Beta Chart

Hemogenyx Pharmaceuticals Annual Data
Trend Feb15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only - - - - 0.08

Hemogenyx Pharmaceuticals Semi-Annual Data
Feb15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.08

Competitive Comparison of Hemogenyx Pharmaceuticals's Beta

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemogenyx Pharmaceuticals's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's Beta falls into.



Hemogenyx Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Hemogenyx Pharmaceuticals  (STU:5HU) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Hemogenyx Pharmaceuticals Beta Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemogenyx Pharmaceuticals (STU:5HU) Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (STU:5HU) Headlines

No Headlines